Introduction {#section1-1534735420924757}
============

The World Health Organization has estimated that modifiable risk factors are responsible for up to a third of cancer cases. Increasing attention is being given to primary prevention campaigns against cancer, and the European code against cancer includes 12 research-based recommendations to reduce its incidence of this disease.^[@bibr1-1534735420924757][@bibr2-1534735420924757]-[@bibr3-1534735420924757]^ Despite these efforts, the incidence of cancer continues to increase every year.^[@bibr4-1534735420924757]^

Breast cancer (BC) is the most frequent cancer among women worldwide and is the leading cause of cancer death among women in middle- and high-income countries.^[@bibr4-1534735420924757]^ The earlier diagnosis of BC and improvements in its treatment have increased the BC survival rate.^[@bibr4-1534735420924757]^ However, repercussions of the disease and its treatment are responsible for physical and neuropsychological symptoms that can impair the health-related quality of life (QoL) of survivors over the medium and long term.^[@bibr5-1534735420924757]^

The World Cancer Research Fund conducted a systematic review of epidemiological studies on women living with BC, including those who recovered from the disease, examining the relationship of life style choices with the prognosis of patients, and the risk of recurrence in survivors; it highlighted the importance of a healthy body weight, the performance of physical exercise, and the consumption of a healthy diet.^[@bibr6-1534735420924757]^ Specifically, the review recommended a diet with high fiber content, low fat (especially saturated fat) content, and a reduced consumption of meat and processed food products. This is similar to the Mediterranean diet (MD) pattern,^[@bibr7-1534735420924757]^ which has been found to reduce the risk of BC, especially the most aggressive tumors, by up to 30% and to increase the likelihood of survival.^[@bibr8-1534735420924757],[@bibr9-1534735420924757],[@bibr10-1534735420924757]^

The relationship between physical exercise and survival after a BC diagnosis was addressed in a recent meta-analysis that included 12 108 women.^[@bibr11-1534735420924757]^ It found that exercise reduced the risk of death from BC by 30% and of death from any cause by 41%, percentages that rose to 50% and 64%, respectively, for women with hormone receptor--positive tumors.^[@bibr11-1534735420924757]^ Physical activity has also been reported to reduce the likelihood of recurrence and metastatic spread.^[@bibr12-1534735420924757]^ Mechanisms underlying the effects of physical activity include the following: reductions in fasting glucose and insulin levels, insulin resistance, insulin-like growth factor-1 secretion, and inflammatory parameters, and increases in Treg and NK cell counts.^[@bibr12-1534735420924757]^ In addition, exercise can reduce oxidative stress and free radical damage by increasing antioxidant and adiponectin levels and decreasing leptin levels (by reducing adipose tissue mass).^[@bibr12-1534735420924757]^

Psychological interventions have been found to improve the health of patients with BC,^[@bibr13-1534735420924757],[@bibr14-1534735420924757]^ and meditation has been used as a complementary approach.^[@bibr15-1534735420924757]^ It has been proposed that meditation can improve the immune system of patients, besides contributing to their emotional healing.^[@bibr16-1534735420924757]^ Various randomized trials have supported the benefits of mindfulness interventions to reduce stress in BC patients and to improve their symptoms and QoL.^[@bibr17-1534735420924757][@bibr18-1534735420924757]-[@bibr19-1534735420924757]^

The primary objective of the present trial was to evaluate whether a triple intervention program (nutrition, physical exercise, and mindfulness) after conventional treatment can improve the QoL, symptoms, and complications of patients with BC and promote their weight control and a healthy lifestyle.

Methods {#section2-1534735420924757}
=======

Participant Recruitment and Inclusion/Exclusion Criteria {#section3-1534735420924757}
--------------------------------------------------------

Participants were recruited from among women with stage IIA-IIB BC attended by the Oncology Mammary Unit of a level-3 hospital in Granada, Southern Spain (University Hospital "Virgen de las Nieves", HUVN), who had completed their cancer treatment more than 12 months earlier. Inclusion criteria were (*a*) age \>18 years; (*b*) residence in the city or metropolitan area of Granada; (*c*) absence of physical or psychological limitations impeding participation in the program; and (*d*) no receipt of specific physical exercise or meditation training or advice from a nutrition specialist.

Before recruitment started, the study was approved by the Clinical Research Ethics Committees of the hospital and the Andalusian Biomedical Research Ethics Committee. At recruitment, the aims of the study were explained to potential participants, who all gave their written informed consent. The study complied with the principles of the Declaration of Helsinki and Spanish Legislation on Clinical Research (Decrees 561/1993 and 033/2004), and the protocol was registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT04150484).

Baseline Interview {#section4-1534735420924757}
------------------

After providing written consent, the women attended an initial interview in which an ad hoc questionnaire was used to gather sociodemographic, lifestyle, and clinical data. These included the following: age, place of residence, type of housing, educational level, marital status, weight changes throughout life, present and previous occupations, self-perceived economic status, medical history, tobacco and alcohol consumption, hours of sleep, and physical activity, among others. The weight and height of participants were measured using a SECA electronic scale. Participants also completed the questionnaire of the European Organization for Research and Treatment of Cancer QLQ-C30 scale^[@bibr20-1534735420924757],[@bibr21-1534735420924757]^ to evaluate their QoL. This 30-item questionnaire has been widely used to assess the health-related QoL of cancer patients in international clinical trials.^[@bibr21-1534735420924757]^ Items are grouped in 5 functional domains (physical \[5 items\], role \[2 items\], cognitive \[2 items\], emotional \[4 items\], and social \[2 items\]), 3 symptom domains (fatigue \[3 items\], pain \[2 items\], nausea and vomiting \[2 items\]), 1 global health QoL domain (2 items), and 6 single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact). All domain/symptom scores were converted to scores ranging from 0 to 100 using the scoring manual.^[@bibr20-1534735420924757]^ Higher scores for the functional and global QoL domains indicate better functioning and QoL, whereas higher scores for the symptom and single items indicate worse symptoms and conditions.

Participants also completed a validated semiquantitative 93-item Food Frequency Questionnaire (<http://bibliodieta.umh.es/files/2011/07/CFA101.pdf>)^[@bibr22-1534735420924757]^ and a 24-hour dietary recall questionnaire. A 14-item Mediterranean diet adherence questionnaire, which excluded alcohol consumption,^[@bibr23-1534735420924757],[@bibr24-1534735420924757]^ was administered in a face-to-face interview.

Participants were then given an appointment a few days later (beginning of January 2016) to provide a fasting blood sample at the Oncology Mammary Unit of the hospital for analysis of glucose, triglycerides, and cholesterol levels (mg/dL), and tumor markers (carcinoembryonic antigen \[CEA\] and cancer antigen \[CA 15.3\]), and a full blood count.

Randomization {#section5-1534735420924757}
-------------

Eligible participants were allocated 1:1 to the intervention group (IG) or control group (CG) in an nonmasked stratified manner using a computerized minimized-randomization procedure with the R program and by an independent statistician blinded to intervention allocation throughout the study, obtaining 2 groups that were similar in age, tumor stage, tumor hormone receptor status (estrogen receptor and her2 status), and hormone treatment.

Intervention Program {#section6-1534735420924757}
--------------------

Women in the IG received a 6-month program on dietary habits, physical activity, and mindfulness. They were asked to keep the contents of the course confidential until the end of the follow-up period.

### Dietary Intervention {#section7-1534735420924757}

In February 2016, the IG took part in three 5-hour workshops on healthy eating patterns for the general population and cancer patients and received information on risk factors for BC and on preventive factors, including the recommendations of the European Code Against Cancer, the benefits of the MD, and the control of weight and energy intake. The workshops emphasized the positive effects of certain foods and food groups (fruits, vegetables, nuts, grains, legumes, fish, dairy products, etc) and the negative effects of others (red/processed meats, high-fat products, etc). Recommendations were given on hydration and drinks to be avoided (sugary and alcoholic) and on the reduction of salt and the use of spices. Other related information included ideas for healthy food preparation and grocery shopping, among others. At the end of the workshop, the women received a leaflet with a summary of the information received and a chart giving flexible dietary options for a 2-week period.

A second "refresher" workshop was held after a 2-month interval, repeating and discussing the main points in the first workshop, addressing doubts and questions. A third meeting was then organized, to which each participant described a healthy menu consisting of a starter, main course, and dessert, and passed on the recipes for the dishes. Besides the sharing of recipes, the aim of this last workshop was to familiarize the women with unknown healthy foods and cooking methods.

### Physical Activity Intervention {#section8-1534735420924757}

During a 7-week period (March-April 2016), women in the IG attended a 60-minute class 3 times per week at the "Cuídate" Support and Research Unit for Oncology Patients. It was run by physiotherapists and health care professionals from the School of Health Sciences (University of Granada). The classes included core, upper limb, and lower limb exercises, targeted stretching sessions focused on the upper limbs and, once a week, Spanish dancing (*Sevillanas* and *Flamenco*). Each exercise session started with a 10-minute warm-up (games, walking fast, etc), followed by a 30-minute period of exercise circuits for different areas of the body, performing each exercise 6 to 8 times, and repeating each circuit 3 times, and it ended with a 10-minute cool-down period of targeted stretching. The weekly dance class started with a 10-minute warm-up (mobilization of ankles, knees, hips, shoulders, and head), followed by a 30-minute period to learn the positions and movements required for dancing *Sevillanas* and *Flamenco*.

### Mindfulness Intervention {#section9-1534735420924757}

During a 4-week period (May 2016), the women in the IG attended a twice-weekly 90-minute mindfulness-based stress reduction (MBSR) session, supervised by an MBSR-trained psychologist involved in the research project. The program was a slight modification of a previously published 8-week MBSR program^[@bibr25-1534735420924757]^ focused on the practice of mindfulness through meditation and yoga.

Follow-up of Breast Cancer Women {#section10-1534735420924757}
--------------------------------

A follow-up of all participants (IG and CG) was conducted at 6 months after the end of the intervention, measuring their weight, QoL, Mediterranean Diet adherence questionnaire, and blood parameters using the same procedures as at baseline. Two main study outcomes were considered: the change between baseline and follow-up in QoL (functional and symptom scales) and complications; and the change in weight, healthy lifestyle habits, and blood parameters. For ethical reasons, the CG received the same intervention program after the follow-up period.

Statistical Analysis {#section11-1534735420924757}
--------------------

The sample size was estimated to achieve a power of 80% to detect a significant postintervention improvement in EORTC QLQ-C30 functional scores (*p* \< .05), based on a previous study,^[@bibr26-1534735420924757]^ calculating a minimum number of 36 women in each study group. The sample size was increased to 45 women per group to allow for possible dropouts.

In a descriptive statistical analysis, mean (standard deviation), and median (25 and 75 percentiles) values were calculated for quantitative variables and percentages for qualitative variables. Student's *t*, Wilcoxon, and/or Mann-Whitney *U* tests were used for between-group comparisons in baseline demographics, QoL, and clinical characteristics, and the nonparametric Wilcoxon test for comparisons between before and after the intervention. The Mann-Whitney *U* test was used to compare differences between CG and IG at the follow-up. *p* \< .05 was considered significant in all tests.

Results {#section12-1534735420924757}
=======

Between September 2015 and November 2015, 100 women attending the Oncology Mammary Unit of the HUVN who had completed their cancer treatment more than 12 months earlier were invited to participate in this study, and eligibility criteria were met by 90 of these. Out of the 75 who initially provided written consent to participation, 3 were lost to the baseline appointment (1 for second cancer diagnosis and 2 for other reasons), leaving a final sample of 72 women (36 in each group). Subsequently, 5 women in the IG and 4 in the CG were lost to the follow-up, leaving a final sample of 31 women in the IG and 32 in the CG ([Figure 1](#fig1-1534735420924757){ref-type="fig"}).

![The CONSORT flow diagram.](10.1177_1534735420924757-fig1){#fig1-1534735420924757}

Baseline Characteristics of Study Population {#section13-1534735420924757}
--------------------------------------------

[Table 1](#table1-1534735420924757){ref-type="table"} displays the baseline sociodemographic data of the IG and CG, and [Table 2](#table2-1534735420924757){ref-type="table"} exhibits their dietary characteristics. No statistically significant between-group differences were found in any of these variables at baseline. The mean age was 48.33 ± 7.72 years in the CG and 51.32 ± 10.15 years in the IG. According to their body mass index values, 21.21% of the CG were overweight and 27.27% were obese; while 29.41% of the IG were overweight and 35.29% were obese. A normal weight was recorded in 51.52% of the CG and in 35.29% of the IG (35.29%). Some physical activity was performed by 39.39% of the CG and by 55.88% of the IG ([Table 1](#table1-1534735420924757){ref-type="table"}). In the CG, 51.52% were ex-smokers, 30.30% had never smoked, and 18.18% were current smokers. In the IG, 29.41% were ex-smokers, 50% had never smoked, and 20.59% were current smokers. Alcoholic beverages were consumed by 81.8% of the CG and 82.4% of the IG ([Table 1](#table1-1534735420924757){ref-type="table"}).

###### 

Baseline Sociodemographic Characteristics of the Study Population.

![](10.1177_1534735420924757-table1)

  Variables                    Control Group (n = 33)   Intervention Group (n = 34)                             
  ---------------------------- ------------------------ ----------------------------- ---- --------------- ---- -------
  Age (years)                  48.33 ± 7.72             41                            54   51.32 ± 10.15   44   59.25
                               N                        \%                            N    \%                   
  BMI (kg/m^2^)                                                                                                 
   Normal weight               17                       51.52                         12   35.29                
   Overweight                  7                        21.21                         10   29.41                
   Obese                       9                        27.27                         12   35.29                
  Residence                                                                                                     
   Urban                       20                       60.61                         19   55.88                
   Rural                       13                       39.39                         15   44.12                
  Education                                                                                                     
   Up to primary school        15                       45.45                         16   47.06                
   Secondary school            7                        21.21                         6    17.65                
   University degree           11                       33.33                         12   35.29                
  Income level                                                                                                  
   Low                         13                       39.39                         11   32.35                
   Middle                      20                       60.61                         23   67.65                
  Marital status                                                                                                
   Single                      4                        12.12                         8    23.53                
   With partner                26                       78.79                         23   67.65                
   Divorced/widowed            3                        9.09                          3    8.82                 
  Employment/labor condition                                                                                    
   Unemployed                  9                        27.27                         10   29.41                
   Employed                    23                       69.70                         23   67.65                
   Retired                     1                        3.03                          1    2.94                 
  Type of occupation                                                                                            
   Sedentary                   10                       30.30                         7    20.59                
   Standing                    17                       51.52                         12   35.29                
   Physical work               6                        18.18                         15   44.12                
  Tobacco habit                                                                                                 
   Never smoked                10                       30.30                         17   50.00                
   Ex-smoker                   17                       51.52                         10   29.41                
   Current smoker              6                        18.18                         7    20.59                
  Alcohol                                                                                                       
   No                          6                        18.2                          6    17.6                 
   Yes                         27                       81.8                          28   82.4                 
  Physical activity                                                                                             
   No                          20                       60.61                         15   44.12                
   Yes                         13                       39.39                         19   55.88                

Abbreviations: SD, standard deviation; P, percentile; BMI, body mass index.

###### 

Baseline Dietary Characteristics of the Study Population.

![](10.1177_1534735420924757-table2)

                                                                                                                                    Control Group (n = 33)   Intervention Group (n = 34)                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------------------------------------------------------------------ -------- ---------------- -------- --------
  Total energy (kcal)                                                                                                               1806.3 ± 626.8           1308.8                                                                               2161.8   1714.0 ± 533.6   1389.0   1976.1
  Carbohydrates (%)                                                                                                                 45.2 ± 11.3              38.2                                                                                 49.4     46.8 ± 7.4       43.1     51.8
  Fat (%)                                                                                                                           38.6 ± 10.7              32.0                                                                                 46.9     36.0 ± 5.8       31.9     39.0
  Proteins (%)                                                                                                                      15.4 ± 5.3               11.5                                                                                 18.3     16.5 ± 4.2       13.5     19.0
  Dietary fiber (g)                                                                                                                 17.2 ± 6.0               13.7                                                                                 21.5     20.0 ± 8.7       14.8     24.5
                                                                                                                                    Control Group (n = 33)   Intervention Group (n = 34^[a](#table-fn3-1534735420924757){ref-type="table-fn"}^)                                      
                                                                                                                                    N                        \%                                                                                   n        \%                        
  Mediterranean diet^[a](#table-fn3-1534735420924757){ref-type="table-fn"},[b](#table-fn4-1534735420924757){ref-type="table-fn"}^                                                                                                                                                    
   Low adherence                                                                                                                    23                       69.7                                                                                 19       55.9                      
   Good adherence                                                                                                                   10                       30.3                                                                                 14       41.2                      

Abbreviations: SD, standard deviation; P, percentile.

One questionnaire of Adherence to Mediterranean diet was not evaluated because of the participant's complete lack of olfaction and taste after breast cancer treatment.

Low adherence (\<9 points); good adherence (≥9 points).

As shown in [Table 2](#table2-1534735420924757){ref-type="table"}, a low MD adherence (\<9 points) was observed in 69.7% of the CG and 55.9% of the IG. The mean caloric intake was 1806.3 kcal in the CG and 1714 kcal in the IG. In the CG, the macronutrient distribution was 45.2% carbohydrates, 38.6% fat, 15.4% proteins, with a fiber intake of 17.2 g. In the IG, it was 46.8% carbohydrates, 36.0% fat, 16.5% proteins, with a fiber intake of 20.0 g ([Table 2](#table2-1534735420924757){ref-type="table"}).

The breast tumor characteristics of the 2 groups are summarized in [Table 3](#table3-1534735420924757){ref-type="table"}.

###### 

Baseline Clinical Characteristics of the Study Population^[a](#table-fn6-1534735420924757){ref-type="table-fn"}^.

![](10.1177_1534735420924757-table3)

                                    Control Group (n = 33)                                      Intervention Group (n = 34)                                                               
  --------------------------------- ----------------------------------------------------------- ----------------------------- ----------------------------------------------------------- -------
  Family history of breast cancer                                                                                                                                                         
   No                               16^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   50.00                         23^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   69.70
   Yes                              16^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   50.00                         10^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   30.30
  Family history of other cancers                                                                                                                                                         
   No                               13                                                          39.39                         13                                                          38.23
   Yes                              20                                                          60.61                         21                                                          61.77
  ER                                                                                                                                                                                      
   Positive                         30^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   93.75                         26^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   78.79
   Negative                         2^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^    6.25                          7^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^    21.21
  HER2                                                                                                                                                                                    
   Positive                         5^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^    15.63                         7^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^    21.21
   Negative                         27^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   84.37                         26^[b](#table-fn7-1534735420924757){ref-type="table-fn"}^   78.79
  Stage                                                                                                                                                                                   
   IIA                              13                                                          39.39                         19                                                          55.88
   IIB                              19                                                          57.57                         13                                                          38.23
   Unknown                          1                                                           3.03                          2                                                           5.88
  Hormone therapy                                                                                                                                                                         
   No                               5                                                           15.15                         4                                                           11.76
   Yes                              28                                                          84.85                         30                                                          88.24

Abbreviations: ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2.

In some groups, the sum of participants differs from the total number because information was missing from medical records.

No data for one woman.

Evaluation of Outcome Variables Pre-and Postintervention {#section14-1534735420924757}
--------------------------------------------------------

All 3 nutrition workshops were completed by 90% of the women in the IG, the exercise program was completed by 70%, and the mindfulness intervention program by 59%. Only 15 patients completed ≥75% of the whole program (3 dietary workshops, 21 physical exercise classes, and 8 mindfulness sessions), mainly due to their entry into employment. The main outcome variables (including QoL and clinical data) were available for all study participants at both baseline and follow-up.

### Quality of Life {#section15-1534735420924757}

In the IG, significant differences were found between baseline and the follow-up at 6 months in physical (73% vs 87% \[*p* = .001\], role 83% vs 100% \[*p* = .05\]), and social functioning (67% vs 100% \[*p* = .019\]), but not in cognitive or global health QoL status (62.5% vs 67% \[*p* = .59\]) or in symptoms, although there was a nonsignificant decrease in fatigue. In the CG, a significant increase was observed in the frequency of dyspnea symptoms (from 0% to 16% \[*p* = .014\]) and fatigue (from 22% to 28% \[*p* = .053\]; [Table 4](#table4-1534735420924757){ref-type="table"}). In the comparison of data at the 6-month follow-up, the IG showed significantly greater improvements in physical and role functioning (*p* = .027 and .028, respectively), while the CG showed a close-to-significant increase in dyspnea symptoms in comparison with the IG (*p* = .066; [Table 5](#table5-1534735420924757){ref-type="table"}).

###### 

Changes in Functional and Symptom Scales of QLQ-C30, Adherence to Mediterranean Diet, and Clinical Markers^[a](#table-fn9-1534735420924757){ref-type="table-fn"}^.

![](10.1177_1534735420924757-table4)

                               Control Group (n = 32)   Intervention Group (n = 31)                                                   
  ---------------------------- ------------------------ ----------------------------- --------- ------------------ ------------------ ------
  Functional scales                                                                                                                   
   Physical functioning        80 (73.3-91.7)           80 (61.7-93.3)                .992      73.3 (58.3-93.3)   86.7 (73.3-93.3)   .001
   Role functioning            91.7 (66.7-100)          91.7 (33.3-100)               .071      83.3 (50-100)      100 (83.3-100)     .05
   Cognitive functioning       66.7 (37.5-100)          66.7 (33.3-83.3)              .270      66.7 (45.8-83.3)   83.3 (33.3-83.3)   .894
   Emotional functioning       66.7 (33.3-91.7)         75 (41.66-83.33)              .095      66.7 (47.9-85.4)   75 (66.7-91.7)     .100
   Social functioning          83.3 (50-100)            91.66 (50-100)                .423      66.7 (45.8-100)    100 (83.3-100)     .019
  Global health status         62.5 (41.7-83.3)         66.7 (43.7-83.3)              .662      62.5 (50-83.3)     66.7 (66.7-83.3)   .589
  Symptom and problem scales                                                                                                          
   Fatigue                     22.2 (0-41.7)            27.8 (2.8-63.9)               .053      33.3 (0-55.5)      22.2 (11.1-44.4)   .693
   Pain                        33.3 (16.7-66.7)         41.7 (20.8-66.7)              .471      33.3 (16.7-66.7)   33.3 (0-66.7)      .759
   Dyspnea                     0 (0-33.3)               16.7 (0-66.7)                 .014      0 (0-33.3)         0 (0-33.3)         .635
   Insomnia                    33.3 (8.3-66.7)          66.7 (0-66.7)                 .545      33.3 (0-66.7)      33.3 (33.3-66.7)   .019
  Adherence to MD                                                                                                                     
   MD score                    7.5 (6-9)                8.0 (7-8)                     .292      7.0 (6-10)         10 (8-11)          .008
  Good adherence MD                                                                                                                   
   n (%)                       10 (31%)                 7 (22%)                       .375      14 (44%)           24 (73%)           .035
   BMI (kg/m^2^)               24.6                     25.5                          .260      26.4               26.7               .270
  Clinical markers                                                                                                                    
   Total cholesterol (mg/dL)   206 (181-121)            188 (172-217)                 0.009     196 (169-245)      181 (163.5-217)    .038
   LDL (mg/dL)                 134 (128-144)            126 (116-141)                 0.049     161 (93-179)       114 (91-152)       .01
   HDL (mg/dL)                 68 (57-73)               59 (54-62)                    0.038     64 (48-72)         57 (55-61)         .046
   Triglycerides (mg/dL)       85 (72-102)              111 (84- 135)                 \<0.001   102 (76-130)       90 (76-110)        .077
   Ca 15.3                     9.6 (7.4-12.9)           12.3 (8.8-14.5)               0.044     10 (9-14)          10 (8-12)          1

Abbreviations: QOL-30, quality of life test for oncology patients; MD, Mediterranean diet; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Ca 15.3, cancer antigen 15.3.

Variables are expressed as medians (IQR). *p* values for comparison of the mean change in variables among women inside the control or intervention groups between baseline and follow-up were obtained using the Mann-Whitney *U* test.

End follow-up: 6 months after intervention program.

###### 

CG Versus IG for Mean Change in Health Variables.

![](10.1177_1534735420924757-table5)

                            CG, n = 32     IG, n = 31     IG Versus CG                                                        
  ------------------------- -------------- -------------- ------------------ -------------- -------------- ------------------ -------------------------------------------------------------------
  Physical functioning      79.2 (15.7)    78.3 (18.9)    −0.89 (17.9)       75.4 (19.5)    85.0 (14.1)    9.6 (14.4)         **.027**
  Social functioning        73.4 (28.4)    78.7 (28.5)    5.2 (37.3)         69.4 (29.8)    83.3 (24.7)    14.0 (32.8)        .429
  Role functioning          81.3 (22.7)    71.9 (32.1)    −9.4 (29.0)        77.4 (25.3)    86.6 (21.3)    9.2 (28.5)         **.028**
  Cognitive functioning     66.7 (33.3)    58.9 (31.7)    **−**7.8 (34.1)    66.1 (29.7)    66.1 (26.4)    0.0 (24.0)         .330
  Global health status      62.2 (26.3)    64.1 (22.7)    1.82 (28.1)        66.9 (23.2)    69.4 (20.2)    2.42 (18.2)        .928
  Fatigue                   26.4 (27.5)    34.7 (32.3)    8.3 (21.9)         30.1 (28.6)    28.3 (19.4)    **−**1.8 (23.9)    .096
  Pain                      39.6 (28.3)    44.8 (30.7)    5.2 (32.4)         37.1 (29.1)    35.5 (28.1)    **−**1.61 (25.2)   .520
  Dyspnea                   17.7 (26.8)    31.3 (35.9)    13.5 (29.2)        17.2 (25.6)    15.1 (25.6)    **−2.2 (27.1)**    **.066**
  Insomnia                  48.0 (36.9)    51.0 (36.9)    3.1 (32.1)         33.3 (32.2)    48.4 (34.3)    15.1 (32.0)        .102
  Emotional                 60.9 (29.2)    66.7 (26.5)    5.73 (24.9)        66.4 (26.7)    73.4 (24.9)    6.99 (31.0)        .950
  MD score                  7.4 (2.2)      7.8 (1.7)      0.31 (1.73)        8.1 (2.9)      9.7 (1.7)      1.57 (2.6)         **.051** ^[b](#table-fn15-1534735420924757){ref-type="table-fn"}^
  High MD adherence n (%)   10 (31.3)      7 (21.9)       −9.4%              13 (41.9)      24 (77.4)      **+35.5%**         **.02** ^[b](#table-fn15-1534735420924757){ref-type="table-fn"}^
  BMI (kg/m^2^)             26.8 (6.0)     27.0 (6.2)     0.22 (1.05)        28.0 (5.0)     27.7 (4.9)     **−0.29 (0.95)**   **.043**
  Weight (kg)               68.9 (14.7)    69.5 (15.0)    0.55 (2.70)        69.8 (12.0)    69.0 (11.7)    **−0.72 (2.42)**   **.052**
  Glucose (mg/dL)           84.5 (10)      86.9 (11.7)    1.85 (9.4)         83.2 (12.7)    87.4 (14.1)    4.2 (18.8)         .905
  TG (mg/dL)                91.4 (31.7)    111.9 (55.3)   21.5 (32.3)        106.8 (40.6)   98.3 (36.8)    **−9.6 (28.1)**    **\<.001**
  TC (mg/dL)                204.9 (29.6)   191.9 (30.3)   **−**13.5 (24.5)   209.4 (44.3)   190.5 (34.8)   **−**12.1 (26.2)   .670
  HDL (mg/dL)               65.9 (8.5)     59.3 (8.4)     −7.1 (8.4)         61.2 (13.2)    62.1 (14.1)    0.92 (6.3)         **.022**
  LDL (mg/dL)               133 (17.9)     122 (26.9)     **−**2.8 (24.5)    195 (226)      117.2 (31.5)   **−**18.6 (21.6)   .113
  CA 15.3 (U/mL)            13.0 (15.6)    13.1 (14.9)    **−**0.14 (1.61)   11.5 (4.3)     11.7 (4.9)     0.55 (3.5)         .684

Abbreviations: CG, control group; IG, intervention group; SD, standard deviation; MD, Mediterranean diet; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CA, cancer antigen.

Variables are expressed as means (SD).

Bold values shows the statistical significance.

*p* values for comparison of the mean change in health variables between control groups and intervention groups were obtained using Mann-Whitney *U* test.

*p* values obtained using Chi-squared test.

### Weight Change and MD Adherence {#section16-1534735420924757}

In the IG, a significant increase between baseline and 6-month follow-up was observed in mean MD adherence score (from 7 to 10 points, *p* = .008) and in the percentage of women with good MD adherence (\>9 points; from 44% to 73% \[*p* = .035\]; [Table 4](#table4-1534735420924757){ref-type="table"}). At the 6-month follow-up, a significant difference between IG and CG was found in the percentage with good MD adherence (73% of IG vs 22% of CG, *p* \< .001), in the mean MD adherence score (8 for CG and 10 for IG, *p* \< .001; [Table 4](#table4-1534735420924757){ref-type="table"}), in weight gain (gain of 550 g for CG vs loss of 720 g for IG, *p* = .05), and in body mass index (*p* = .04; [Table 5](#table5-1534735420924757){ref-type="table"}).

### Clinical Measurements {#section17-1534735420924757}

Between baseline and the end of the follow-up, total cholesterol, low-density lipoprotein, and high-density lipoprotein were significantly reduced in both the IG and CG, while triglycerides were significantly reduced in the IG and significantly increased in the CG; cancer antigen 15.3 was also significantly increased in the CG ([Table 4](#table4-1534735420924757){ref-type="table"}). At the end of the follow-up, mean triglyceride levels were decreased in the IG (−9.6 mg/dL) and increased in the CG (+21.5 mg/dL), a significant between-group difference (*p* \< .001; [Table 5](#table5-1534735420924757){ref-type="table"}). Low-density lipoprotein and high-density lipoprotein cholesterol levels were also improved in the IG in comparison to the CG ([Table 5](#table5-1534735420924757){ref-type="table"}).

Discussion {#section18-1534735420924757}
==========

The integrative intervention program proposed in this study proved to be an effective approach to improve the QoL of BC survivors, although the effect was only moderate after the established follow-up period (6 months). It also enhanced healthy lifestyle habits, significantly increasing adherence to the MD, and weight control.

It has previously been reported that the functions, symptoms, and complications of BC patients can be improved by integrative programs that promote a healthy lifestyle, including diet, physical activity, and/or mindfulness.^[@bibr27-1534735420924757],[@bibr28-1534735420924757]^ Cancer survivors are known to face multiple physical and emotional challenges.^[@bibr5-1534735420924757]^ It has been observed that women who survive BC experience emotional difficulties that can affect their QoL and increase the risk of complications.^[@bibr13-1534735420924757],[@bibr14-1534735420924757],[@bibr29-1534735420924757]^ In the present study, some of the most frequent and persistent problems of BC survivors (impaired QoL, fatigue, and physical deconditioning) were improved at 6 months after the integrative intervention, with a significant increase in physical and role functioning (*p* = .027 and .028, respectively). At the end of the follow-up, fatigue, which has been related to physical functionality in cancer patients,^[@bibr30-1534735420924757]^ was less frequently reported by women who had participated in the intervention program than by those who had not. There was also a tendency for dyspnea to be more frequent in the CG than in the IG (*p* = .066).

The "Continuous Update Project-CUP" program of the WCRF/AICR (World Cancer Research Fund and the American Institute for Cancer Research)^[@bibr31-1534735420924757]^ described a positive relationship between certain lifestyle characteristics and improved survival in patients with BC. In this line, the wide European prospective cohort study found that adherence to WCRF/AICR recommendations on diet, physical activity, and body fatness was inversely related to all studied causes of death, including death from cancer; and a decrease in adiposity and an increase in plant-based food consumption were the factors most strongly associated with a reduced risk of death.^[@bibr7-1534735420924757]^

The present results demonstrate that this type of integrative intervention program can promote a healthy lifestyle, including adherence to the MD, measured using a simple scale of 14 items related to the key characteristics of this dietary pattern.^[@bibr23-1534735420924757],[@bibr24-1534735420924757]^ Adherence to the MD was significantly greater in the women who received the program than in the controls after 6 months of follow-up, and this was related to their weight loss. However, a longer follow-up is required to verify the maintenance of MD adherence over the longer term.

Before the intervention, a majority of the women were overweight or obese, which has been associated with a higher risk of BC and a worse prognosis.^[@bibr32-1534735420924757]^ At 6 months after the intervention, the weight of the women in the CG had increased versus baseline by a mean of 0.55 kg, whereas the weight of those in the IG had decreased by a mean of 0.72 kg (*p* = .05). An even greater weight loss was observed in the 15 women who attended all 3 dietary workshops (data not shown). A postdiagnostic weight gain of up to 8 kg has been reported in 68% of BC patients at 3 years postdiagnosis.^[@bibr33-1534735420924757]^ Besides being a risk factor for both pre- and postmenopausal BC and its recurrence, being overweight is significantly associated with mortality for all causes, including BC.^[@bibr6-1534735420924757]^ Specifically, the risk of mortality from BC has been estimated to increase by 8% to 29% for each body mass index unit increase in pre- and postmenopausal BC survivors.^[@bibr34-1534735420924757],[@bibr35-1534735420924757]^ Many studies have shown that BC survivors can benefit from interventions to improve diet and exercise, possibly due to a reduction in weight^[@bibr36-1534735420924757]^ and body fat.^[@bibr28-1534735420924757]^

Multiple cellular and molecular pathways are implicated in the link between adiposity and the risk and prognosis of cancer. Obesity produces systemic changes in various metabolic and endocrine pathways that can lead to hyperinsulinemia, increased estradiol levels, and a state of chronic inflammation, among other systemic effects.^[@bibr6-1534735420924757]^

Importantly, most of these systemic effects can promote multiple hallmarks of cancer, including sustained proliferative signaling, resistance to cell death, activation of invasion/metastasis, induction of angiogenesis, genome instability/mutation, and inflammation. For example, in the case of BC in postmenopausal women, an increase in adiposity is related to greater aromatase activity and, therefore, to an increase in the production of estrogen, which can stimulate the proliferation of breast tissue of hormonally dependent tumors, favoring the development of BC.^[@bibr37-1534735420924757]^

Regular physical exercise is a fundamental pillar of cancer prevention, and multiple mechanisms underlie its protective effects.^[@bibr38-1534735420924757][@bibr39-1534735420924757][@bibr40-1534735420924757][@bibr41-1534735420924757]-[@bibr42-1534735420924757]^ Thus, it decreases insulin resistance, improves immune function, reduces hormonal production, counteracts free radicals, and diminishes leptin, among other actions.^[@bibr12-1534735420924757],[@bibr43-1534735420924757]^ It has been reported that physical activity contributes to increasing survival rates after BC remission and to preventing relapse in BC patients.^[@bibr43-1534735420924757]^ It is also important to take into account its preventive effect against obesity-associated comorbidities such as diabetes, cardiovascular disease, and hypertension, which increase the risk of relapse and cancer death as well as non-cancer-specific deaths.^[@bibr44-1534735420924757]^ Accordingly, regular exercise not only reduces the risk of recurrence and metastases in patients with BC, but also enhances their weight control and overall health.^[@bibr45-1534735420924757]^

MBSR programs have been reported to significantly improve the perceived stress, depression, anxiety,^[@bibr15-1534735420924757],[@bibr46-1534735420924757]^ quality of sleep,^[@bibr17-1534735420924757]^ fear,^[@bibr18-1534735420924757]^ and mental health^[@bibr46-1534735420924757]^ of BC survivors, increasing their QoL.^[@bibr17-1534735420924757],[@bibr18-1534735420924757]^ The women participating in the present program showed no statistically significant changes in the emotional domain, but achieved a significant improvement (*p* = .019) in social functioning.

Different international scientific societies have published recommendations for a healthy lifestyle, mainly related to diet and physical exercise; however, they have not yet been integrated in oncology rehabilitation units for cancer survivors. The present study contributes to increasing evidence that an integrative approach can improve the QoL of BC survivors, especially in relation to their physical, social, and functional well-being, and can help to reduce their symptoms and associated complications.

Strengths and Limitations {#section19-1534735420924757}
=========================

Strengths of this study include the population of high-risk BC survivors with elevated high rates of inactivity and obesity; the targeting of early survivorship; the randomized controlled trial design; and the wide range of study outcomes, including both subjective and objective measures. Limitations include the relatively low adherence rate to the intervention, with only 15 patients completing \>75% of program sessions. Work scheduling problems meant that the majority of the women could not attend all physical exercise and mindfulness sessions. The small sample size limits the reliability of the estimates and the capacity to detect subtle effects.

Conclusion {#section20-1534735420924757}
==========

The results of this study indicate that an integrative intervention program on diet, physical activity, and mindfulness has positive effects on the QoL (physical, role, and social function) of BC patients and promotes healthy lifestyle habits, weight loss, and an improved serum lipid profile.

The elevated incidence and prevalence of BC has increased research interest in complementary treatments for cancer survivors. The present findings support the implementation of complementary interventions that combine diet, exercise, and stress-reduction techniques. This type of integrative program may also help prevent BC recurrence and the development of secondary tumors. Further studies are required to confirm the strength of scientific evidence for these novel complementary interventions. Greater public health efforts are warranted to implement integrative oncology interventions that promote and maintain a healthy lifestyle in BC survivors.
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